the front-hairline thing is androgen-driven, so you’re mostly going to land on fin/dut + minoxidil regardless. that part’s settled. what i went looking for instead was why everyone parrots “give it a year,” and the answer is more boring than people make it. stuff worth reading, in order of how much it changed my thinking: - the original fin pivotal trials. the 12-month endpoint isn’t a biological clock, it’s the regulatory measurement window (target-area hair counts in a 1cm circle, macrophotography). people treat “a year” as when the drug works. it’s when the trial measured. you’ll see shedding stabilize well before that. - anything on oral minoxidil dosing + the BP/edema monitoring. the cardiac-history exclusions in those cohorts are the part the reddit threads skip. - topical fin PK papers. serum levels are lower than oral but not zero, and the assay variability is wide enough that one “undetectable” draw rules out almost nothing. thing i can’t find a clean source on: whether perceived “plateaus” at month 8-10 are real or just photo-angle and lighting drift between progress pics. ime nobody standardizes the lighting and it shows. fwiw not medical advice, just what i’ve read.
edit: realized I said that wrong
the photo-standardization problem at months 8-10 is probably more confound than people admit - uncontrolled lighting, angle, and whether you towel-dried differently that morning are exactly the variables the trial macrophotography protocol was designed to eliminate. consumer progress pics are almost uninterpretable for the same reason unblinded self-report is noisy: you see what you’re hoping to see.
The case for your read is strong, the macrophotography protocol exists precisely to strip out towel-drying and angle, so consumer pics inherit all the noise it was built to remove. Where I’d gently push, though: even the standardized trial counts flatten after about a year, so a genuine plateau sits in the cleanest data we have. Pinning the month 8-10 stall entirely on lighting drift quietly assumes the underlying curve is still climbing, and mostly it isn’t. Both things are true at once.
“mostly it isn’t” is doing real work in that sentence, and the Phase III data earns it - hair counts in the original pivotal studies peak somewhere in the 12-24 month range on continuous fin and then trend slowly downward even with perfect adherence, which is a genuine biological ceiling, not a measurement artifact. so the lighting-drift confound and the real plateau can both be operating at month 8-10, and the question is which one dominates in any individual case - something you can’t disentangle from consumer progress pics regardless of how carefully you frame the claim. the adherence angle is also underweighted in these discussions. fin is daily dosing over a 12+ month window and people aren’t always actually tracking whether their real-world adherence held up. I use CareClinic’s check-in reminders for a different daily rx and the gaps you find when you go back through the log are not what you’d assume - which applies here too if you’re trying to separate drug effect from adherence effect in a perceived stall. attributing the whole thing to biology or lighting without knowing the adherence picture is where a lot of these self-reports go sideways.